THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [5.12] ID: TIP-MED-000080

Antacids (Aluminium Hydroxide + Magnesium Hydroxide + Simethicone / Magaldrate / Oxetacaine Combinations)

Active Ingredient / Scientific Identity: Antacids • Class: Local Gastric Acid Neutralisers (Non-Systemic Antacids) with Antiflatulent (Simethicone) or Mucosal Anaesthetic (Oxetacaine)

⚖️ Compare Profile
Generic / Entity NameAntacids (Aluminium Hydroxide + Magnesium Hydroxide + Simethicone / Magaldrate / Oxetacaine Combinations) ([5.12])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassLocal Gastric Acid Neutralisers (Non-Systemic Antacids) with Antiflatulent (Simethicone) o
Available Dosage FormsChewable Tablets & Oral Suspensions (typically 5–10 mL containing Al(OH)3 200–400 mg + Mg(OH)2 100–400 mg or M
Regulatory ClassificationNon-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommend
Key Warning & Review DateRenal: Strictly avoid chronic Mg/Al antacids if eGFR <30 mL/min! Hepatic: Avoid high-sodium effervescent antacids in cirrhoti
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Non-Schedule / OTC or Schedule K Permitted Preparati✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Antacids (Aluminium Hydroxide + Magnesium Hydroxide + Simethicone / Magaldrate / Oxetacaine Combinations) (TIP-MED-000080, Reference Code [5.12]) is classified under Gastrointestinal & Hepatobiliary Medicines (Ch 05) as a Local Gastric Acid Neutralisers (Non-Systemic Antacids) with Antiflatulent (Simethicone) or Mucosal Anaesthetic (Oxetacaine). Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 05 [5.12], p. 65): Digene Gel / Tablets (Abbott), Gelusil MPS (Pfizer), Mucaine Gel (Pfizer—contains Oxetacaine), Siloxogene, Polycrol, Aciloc-RD/Antacid syrups — Strengths & Dosage Forms: Chewable Tablets & Oral Suspensions (typically 5–10 mL containing Al(OH)3 200–400 mg + Mg(OH)2 100–400 mg or Magaldrate 400–540 mg + Simethicone 20–50 mg ± Oxetacaine 10 mg/5 mL)
Representative Indian Market Examples (Edition 2.7 Ch 05 [5.12], p. 65): Digene Gel / Tablets (Abbott), Gelusil MPS (Pfizer), Mucaine Gel (Pfizer—contains Oxetacaine), Siloxogene, Polycrol, Aciloc-RD/Antacid syrups — Strengths & Dosage Forms: Chewable Tablets & Oral Suspensions (typically 5–10 mL containing Al(OH)3 200–400 mg + Mg(OH)2 100–400 mg or Magaldrate 400–540 mg + Simethicone 20–50 mg ± Oxetacaine 10 mg/5 mL)
Dosage Forms & Available Strengths:
Chewable Tablets & Oral Suspensions (typically 5–10 mL containing Al(OH)3 200–400 mg + Mg(OH)2 100–400 mg or Magaldrate 400–540 mg + Simethicone 20–50 mg ± Oxetacaine 10 mg/5 mL)
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Local Gastric Acid Neutralisers (Non-Systemic Antacids) with Antiflatulent (Simethicone) or Mucosal Anaesthetic (Oxetacaine) acting on target receptor/enzyme pathways in Gastrointestinal & Hepatobiliary Medicines (Ch 05): clinical efficacy is mediated via Local Gastric Acid Neutralisers (Non-Systemic Antacids) with Antiflatulent (Simethicone) or Mucosal Anaesthetic (Oxetacaine) for Rapid symptomatic relief of acute hyperacidity, heartburn, acid indigestion, sour eructation, and bloating/flatulence..

4. Therapeutic Indications & Evidence-Supported Uses

  • Rapid symptomatic relief of acute hyperacidity, heartburn, acid indigestion, sour eructation, and bloating/flatulence

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: 10 mL to 15 mL suspension (or 2 chewable tablets, chewed thoroughly) 3 to 4 times daily as needed (SOS), taken 1 hour AFTER meals and at bedtime. Follow physician prescription.

Administration & Meal Timing: Take 1 hour AFTER meals and at bedtime (if taken on an empty stomach, antacids empty into the duodenum within 20–30 minutes; when taken 1 hour after a meal, food buffers and slows gastric emptying, extending acid neutralisation to 2–3 hours!). | 1 hour after breakfast, lunch, and dinner, and at bedtime (or SOS for acute heartburn).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Strictly avoid chronic Mg/Al antacids if eGFR <30 mL/min! Hepatic: Avoid high-sodium effervescent antacids in cirrhotic ascites.
Elimination & Renal Adjustment:
Renal: Strictly avoid chronic Mg/Al antacids if eGFR <30 mL/min! Hepatic: Avoid high-sodium effervescent antacids in cirrhotic ascites.
Hepatic Impairment Considerations:
Renal: Strictly avoid chronic Mg/Al antacids if eGFR <30 mL/min! Hepatic: Avoid high-sodium effervescent antacids in cirrhotic ascites.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Avoid Magnesium- and Aluminium-containing antacids in severe Chronic Kidney Disease (eGFR <30 mL/min) due to risk of fatal hypermagnesaemia and aluminium toxicity. Check sodium content in alginate/bicarbonate preparations (e.g., Gaviscon/Eno) in patients with heart failure, cirrhosis, or severe hypertension.

Key Clinical Precautions: Renal: Strictly avoid chronic Mg/Al antacids if eGFR <30 mL/min! Hepatic: Avoid high-sodium effervescent antacids in cirrhotic ascites.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Magnesium hydroxide causes osmotic loose stools/diarrhoea; Aluminium hydroxide causes constipation (combined Al+Mg formulations balance bowel effects, though mild diarrhoea or constipation may still occur), chalky taste, oral numbness (with Mucaine/oxetacaine).
  • Hypermagnesaemia (areflexia, respiratory depression, heart block) and aluminium neurotoxicity/osteomalacia in CKD, hypophosphataemia (aluminium binds dietary phosphate in the gut with chronic excess use).
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Universal Chelation & pH Interaction Alert: Antacids chelate or alter the pH-dependent dissolution of Fluoroquinolones (ciprofloxacin, levofloxacin), Tetracyclines (doxycycline), Oral Iron, Levothyroxine, Bisphosphonates, Itraconazole, Ketoconazole, Cefuroxime, Cefpodoxime, Rosuvastatin, Gabapentin, Digoxin, and Enteric-Coated Tablets (Bisacodyl, Aspirin EC, PPIs)
  • Maintain a strict 2-hour window BEFORE or 2–4 hours AFTER taking any other oral medicine!

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: For chewable tablets (Digene/Gelusil): chew the tablets thoroughly into a fine paste before swallowing and follow with half a glass of water—swallowing whole antacid tablets prevents rapid acid neutralisation. Shake liquid bottles well. Never take an antacid at the same time as your morning BP, thyroid, diabetes, or antibiotic tablets (keep a 2-hour gap).
  • Meal & Clock Timing Instruction: Take 1 hour AFTER meals and at bedtime (if taken on an empty stomach, antacids empty into the duodenum within 20–30 minutes; when taken 1 hour after a meal, food buffers and slows gastric emptying, extending acid neutralisation to 2–3 hours!). (1 hour after breakfast, lunch, and dinner, and at bedtime (or SOS for acute heartburn).)
  • Missed Dose Protocol: Used SOS for symptom relief; do not double.
  • Geriatric Dispensing Pearl: Elderly CGHS patients frequently self-medicate with Digene/Gelusil alongside their morning or night prescription pile, inadvertently chelating their levothyroxine, iron, or ciprofloxacin. Always place antacids in a separate 1-hour post-meal window.

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Chewable Tablets & Oral Suspensions (typically 5–10 mL containing Al(OH)3 200–400 mg + Mg(OH)2 100–400 mg or Magaldrate 400–540 mg + Simethicone 20–50 mg ± Oxetacaine 10 mg/5 mL)

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 05 [5.12] (p. 65)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.